Fiche société
UCB Biopharma SRL
Traitements, essais et publications liés.
Traitements29programmes
Essais20liés
Publications17liées
SourceDBlocale
Traitements
29| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BrivaracetamThis trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment. | Épilepsie | Phase 3 | À vérifier | United States, Belgium, Czechia, France, Germany, Hungary, Italy, Japan, … | À vérifier |
| Brivaracetam Film-coated tabletThe purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy. | Épilepsie | Phase 3 | À vérifier | United States, Georgia, Italy, Romania, Slovakia | À vérifier |
| Brivaracetam oral solutionThe purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy. | Épilepsie | Phase 3 | À vérifier | United States, Georgia, Italy, Romania, Slovakia | À vérifier |
| Dapirolizumab pegolThe purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment. | Lupus | Phase 3 | À vérifier | United States, Argentina, Belgium, Bulgaria, Canada, Chile, China, Colombia, … | À vérifier |
| DZPThe purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. | Lupus | Phase 3 | À vérifier | United States, Argentina, Belgium, Canada, Chile, China, Denmark, France, … | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | China | À vérifier |
| SPIRIT — SLC6A1-NDD Prospective Longitudinal Natural History StudyThe overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease. | Épilepsie | À vérifier | À vérifier | United States, France, Spain | À vérifier |
| ZilucoplanDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Myasthénie, Sclérose latérale amyotrophique, SEP | Phase 2/3 | À vérifier | United States, Italy, Poland, South Korea, United Kingdom | À vérifier |
| zilucoplan (RA101495)The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. | Myasthénie | Phase 3 | À vérifier | United States, Canada, France, Germany, Italy, Japan, Norway, Poland, … | À vérifier |
| ZilucoplanDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2/3 | À vérifier | United States | À vérifier |
| BrivaracetamThis trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment. | Épilepsie | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, India, Mexico | À vérifier |
| ZilucoplanThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. | Myasthénie | Phase 3 | À vérifier | United States, Poland, United Kingdom | À vérifier |
| BrivaracetamThis trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment. | Épilepsie | Phase 3 | À vérifier | United States, Georgia, Italy, Romania, Slovakia, Spain, Ukraine | À vérifier |
| DZPThe purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. | Lupus | Phase 3 | À vérifier | United States, Argentina, Belgium, Canada, Chile, China, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Peru, Poland, Puerto Rico, Serbia, South Korea, Spain, … | À vérifier |
| Dapirolizumab pegolThe purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment. | Lupus | Phase 3 | À vérifier | United States, Argentina, Belgium, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Greece, Hungary, Italy, Japan, Mexico, Peru, Philippines, Poland, Puerto Rico, Romania, … | À vérifier |
| zilucoplan (RA101495)The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. | Myasthénie | Phase 3 | À vérifier | United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom | À vérifier |
| ZilucoplanThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. | Myasthénie | Phase 2/3 | À vérifier | United States, Italy, Poland, South Korea, United Kingdom | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 2/3 | À vérifier | Italy, Japan, Poland, Turkey (Türkiye) | À vérifier |
| ZilucoplanThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. | Myasthénie | Phase 3 | À vérifier | Italy, Poland, South Korea, United Kingdom | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | Italy, Japan, Poland, Taiwan, Turkey (Türkiye) | À vérifier |
| SPIRIT — SLC6A1-NDD Prospective Longitudinal Natural History StudyThe overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease. | Épilepsie | À vérifier | À vérifier | United States, France, Spain | À vérifier |
| BrivaracetamThis trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment. | Épilepsie | Phase 3 | À vérifier | United States, Belgium, Czechia, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Spain | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States, Canada, China, Japan | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 4 | À vérifier | China | À vérifier |
| Brivaracetam Film-coated tabletThe purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy. | Épilepsie | Phase 3 | À vérifier | United States, Georgia, Italy, Romania, Slovakia | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | À vérifier | |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States, Canada, Czechia, Denmark, France, Georgia, Germany, Italy, Japan, Poland, Russia, Serbia, Spain, Taiwan | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Russia, Serbia, Spain, Taiwan, United Kingdom | À vérifier |
| rozanolixizumabThe purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG). | Myasthénie | Phase 3 | À vérifier | United States, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russia, Spain, Taiwan | À vérifier |
Essais cliniques
20| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| rozanolixizumab | Myasthénie | Phase 3 | NCT04124965 | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | COMPLETED |
| rozanolixizumab | Myasthénie | Phase 3 | NCT03971422 | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | COMPLETED |
| rozanolixizumab | Myasthénie | Phase 3 | NCT04650854 | A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | COMPLETED |
| rozanolixizumab | Myasthénie | Phase 3 | NCT07465289 | A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | NOT_YET_RECRUITING |
| Brivaracetam Film-coated tablet | Épilepsie | Phase 3 | NCT06315322 | A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | ACTIVE_NOT_RECRUITING |
| rozanolixizumab | Myasthénie | Phase 4 | NCT07246564 | Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | RECRUITING |
| rozanolixizumab | Myasthénie | Phase 3 | NCT07463521 | MyVision — A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | RECRUITING |
| Brivaracetam | Épilepsie | Phase 3 | NCT04715646 | A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures | RECRUITING |
| SPIRIT — SLC6A1-NDD Prospective Longitudinal Natural History Study | Épilepsie | À vérifier | NCT07531511 | SPIRIT — SLC6A1-NDD Prospective Longitudinal Natural History Study | RECRUITING |
| rozanolixizumab | Myasthénie | Phase 3 | NCT06540144 | An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION |
| Zilucoplan | Myasthénie | Phase 3 | NCT06435312 | ziMyG+ — An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION |
| rozanolixizumab | Myasthénie | Phase 2/3 | NCT06149559 | roMyG — A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Myasthénie | Phase 2/3 | NCT06055959 | ziMyG — A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | RECRUITING |
| zilucoplan (RA101495) | Myasthénie | Phase 3 | NCT04225871 | RAISE-XT — Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis | COMPLETED |
| Dapirolizumab pegol | Lupus | Phase 3 | NCT04976322 | A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |
| DZP | Lupus | Phase 3 | NCT06617325 | PHOENYCS FLY — A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING |
| Brivaracetam | Épilepsie | Phase 3 | NCT04666610 | EXPAND — A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | COMPLETED |
| Zilucoplan | Myasthénie | Phase 3 | NCT06471361 | A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis | COMPLETED |
| Brivaracetam | Épilepsie | Phase 3 | NCT00150800 | This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
Publications
17| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Brivaracetam oral solution | Seizure Clusters: Current Concepts in Definition and Treatment. | Journal of clinical medicine | ||
| Brivaracetam oral solution | Bioequivalence and Safety Assessment of Brivaracetam Dry Syrup Compared With Tablets in Healthy Japanese Participants: Results From Two Randomized Single- and Multiple-Dose Trials. | Clinical pharmacology in drug development | ||
| Brivaracetam Film-coated tablet | Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet. | Clinical pharmacology in drug development | ||
| Dapirolizumab pegol | Targeting CD40 with dapirolizumab pegol: a new treatment for systemic lupus erythematosus. | Lancet (London, England) | ||
| DZP | Arisaematis Rhizoma protects against refractory status epilepticus via inhibiting caspase-1-mediated neuroinflammation. | Phytomedicine : international journal of phytotherapy and phytopharmacology | ||
| DZP | Diazepam induces mitotic defects and cytotoxicity through modulation of tubulin and Eg5. | Chemico-biological interactions | ||
| DZP | UPLC-ESI-QToF-MS/MS profiling and anxiolytic-like effects of Simira paraensis (Baill.) Steyerm bark. | Journal of pharmaceutical and biomedical analysis | ||
| Zilucoplan | Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases. | Journal of neuroimmunology | ||
| Zilucoplan | A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis. | JAAD case reports | ||
| Dapirolizumab pegol | Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet (London, England) | ||
| Dapirolizumab pegol | Dapirolizumab pegol improves SLE disease activity in phase III trial. | Nature reviews. Rheumatology | ||
| DZP | Variation in resistance and survival of the European bitterling fish across a gradient of Sinanodonta woodiana expansion. | Oecologia | ||
| Zilucoplan | Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis. | Current medical research and opinion | ||
| Zilucoplan | Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes. | Journal of immunology (Baltimore, Md. : 1950) | ||
| Zilucoplan | Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences. | Acta neurologica Belgica | ||
| Zilucoplan | Nipocalimab (Imaavy) for myasthenia gravis. | The Medical letter on drugs and therapeutics | ||
| Zilucoplan | Inebilizumab (Uplizna) for myasthenia gravis. | The Medical letter on drugs and therapeutics |